Eledon stockholders approve increase in authorized common shares from 300M to 450M

Eledon Pharmaceuticals, Inc.

Elected three Class III directors: David-Alexandre C. Gros, M.D., Jan Hillson, M.D., James Robinson for terms ending 2029.
Authorized share increase approved with 52.3M for, 3.7M against, 294k abstain.
Ratified Deloitte & Touche as independent auditor for FY 2026.
Certificate of Amendment effective June 22, 2026, filed with Delaware Secretary of State.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Eledon Pharmaceuticals, Inc.: Increased number of authorized shares of common stock from 300,000,000 to 450,000,000 (effective 2026-06-18).

Change: charter amendment
Effective: 2026-06-18

Exact text from the filing

the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Authorized Share Increase Amendment”) to the Company’s Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) to amend the Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 shares.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Eledon Pharmaceuticals, Inc. shareholders approved Approval of amendment to Certificate of Incorporation to increase authorized shares of common stock from 300,000,000 to 450,000,000 shares at the 2026-06-18 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2026-06-18

Exact text from the filing

The results of the stockholders’ vote with respect to the approved amendment were as follows: For Against Abstain Broker Non-Vote 52,305,057 3,739,735 294,086 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Eledon Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-06-18 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-18

Exact text from the filing

The results of the stockholders’ vote with respect to the ratification were as follows: For Against Abstain Broker Non-Vote 56,010,539 252,240 76,099 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Eledon Pharmaceuticals, Inc. shareholders approved Election of Class III Directors at the 2026-06-18 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-18

Exact text from the filing

The results of the stockholders’ vote with respect to the election of the Class III Directors were as follows: Nominee Term Expiring For Withhold Broker Non-Vote David-Alexandre C. Gros, M.D. 2029 36,633,821 426,888 19,278,169 Jan Hillson, M.D. 2029 33,081,275 3,979,434 19,278,169 James Robinson 2029 30,916,807 6,143,902 19,278,169

View on SEC.gov

189 governance changes filed in the last 30 days. Browse all governance changes →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-277653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.